Health
FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.
OriginalSourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedPublished16:59 UTCSourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedPublished16:59 UTC
“FDA orders new warning on GLP-1 drugs over potential risk of blindness”
“The makers of GLP-1 weight loss drugs such as Ozempic, Wegovy and Mounjaro must add a warning label about a possible link to permanent vision loss , the US Food and Drug Administration has said.”
FDA adds warning about possible link between GLP-1 drugs and NAION
Key points
- FDA orders new warning labels for GLP-1 drugs like Ozempic and Wegovy.
- Warning cites potential link to permanent vision loss via NAION.
- Decision based on clinical trials, observational studies, and 2024 article.
- Healthcare providers urged to consider stopping GLP-1 if NAION signs appear.
- Manufacturers must update labeling to reflect the potential risk.
Other reports
- SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS NewsSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News
“FDA warns of rare vision-loss side effect from GLP-1 drugs”
- SourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at MintSourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at Mint
- SourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars TechnicaSourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars Technica
“GLP-1 drugs may increase risk of vision loss from rare condition, FDA warns”
- SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The IndependentSourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent
- SourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global NewsSourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global News
- SourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBCSourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBC
“Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness”
- SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The GuardianSourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Guardian
“FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications”
- SourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLineSourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLine
“FDA flags possible risk of rare eye condition with GLP-1 drugs, orders new safety warning”
How it got here
The National publishes the article.
concise.news reads it.
Grouped with 8 other reports as story 8.
The Brief ranks it 8th.
8 8 FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.